As the end of the year approaches, the pace at which multinational pharmaceutical giants are deploying the next generation of weight loss drugs shows no sign of slowing down. Recently, Eli Lilly released the latest data on a novel weight loss drug; and Pfizer is once again buying the Chinese company's next-generation GLP-1 drug. On the other hand, with Eli Lilly's tipopeptides being included in medical insurance in 2026, and Novo Nordisk's core patent for simeglutide in China about to expire, the overall landscape of the domestic GLP-1 metabolite market will also “change.” Industry insiders expect that the future supply of GLP-1 drugs will be far greater than the PD-1 target drugs that pharmaceutical companies piled up in the previous round. And with the launch of a large number of generic drugs, in 2026, a price war for GLP-1 drugs is about to begin. According to incomplete statistics, up to now, 8 domestically produced simeglutide have been marketed and accepted, from Huisheng Biotech, Chengdu Beite, Shiyao Group, Hangzhou Central America, East China, Zhuhai Federation, Qilu, Pearl, and Jiuyuan Gene.

As the end of the year approaches, the pace at which multinational pharmaceutical giants are deploying the next generation of weight loss drugs shows no sign of slowing down. Recently, Eli Lilly released the latest data on a novel weight loss drug; and Pfizer is once again buying the Chinese company's next-generation GLP-1 drug. On the other hand, with Eli Lilly's tipopeptides being included in medical insurance in 2026, and Novo Nordisk's core patent for simeglutide in China about to expire, the overall landscape of the domestic GLP-1 metabolite market will also “change.” Industry insiders expect that the future supply of GLP-1 drugs will be far greater than the PD-1 target drugs that pharmaceutical companies piled up in the previous round. And with the launch of a large number of generic drugs, in 2026, a price war for GLP-1 drugs is about to begin. According to incomplete statistics, up to now, 8 domestically produced simeglutide have been marketed and accepted, from Huisheng Biotech, Chengdu Beite, Shiyao Group, Hangzhou Central America, East China, Zhuhai Federation, Qilu, Pearl, and Jiuyuan Gene.